Sickle Cell Trait Doesn't Up Mortality Risk in U.S. Soldiers

Share this content:
Sickle Cell Trait Doesn't Up Mortality Risk in U.S. Soldiers
Sickle Cell Trait Doesn't Up Mortality Risk in U.S. Soldiers

WEDNESDAY, Aug. 3, 2016 (HealthDay News) -- Sickle cell trait is not associated with a higher risk of death than absence of the trait, but it is associated with a significantly increased risk of exertional rhabdomyolysis, according to a study published in the Aug. 4 issue of the New England Journal of Medicine.

D. Alan Nelson, Ph.D., from the Stanford University School of Medicine in California, and colleagues examined whether the risks of exertional rhabdomyolysis and death varied according to sickle cell trait status. Data were included for 47,944 black soldiers who had undergone hemoglobin AS testing and were on active duty in the U.S. Army.

The researchers found that the risk of death did not differ significantly for soldiers with versus those without the sickle cell trait (hazard ratio [HR], 0.99; 95 percent confidence interval [CI], 0.46 to 2.13); however, the trait correlated with significantly elevated adjusted risk of exertional rhabdomyolysis (HR, 1.54; 95 percent CI, 1.12 to 2.12). The magnitude of this effect was similar to that associated with tobacco use versus non-use (HR, 1.54; 95 percent CI, 1.23 to 1.94) and to that associated with having a body mass index of 30 kg/m² or more versus less than 25 kg/m² (HR, 1.39; 95 percent CI, 1.04 to 1.86). The effect was less than that associated with recent statin use or antipsychotic agent use.

"Sickle cell trait was not associated with a higher risk of death than absence of the trait, but it was associated with a significantly higher risk of exertional rhabdomyolysis," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »